Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH

03-March-2026 / 17:45 CET/CEST

Rellingen, March 03, 2026 – Viromed Medical AG (“Viromed“; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has today signed a letter of intent to acquire all shares in relyon plasma GmbH, which is based in Regensburg (“relyon”). The purchase price is currently under negotiation, but Viromed estimates it will be in the low- to mid-double-digit million euro range. The conclusion of the corresponding share purchase agreement is expected to be concluded in the second quarter of 2026 and will be subject to a successful due diligence review and the fulfilment of customary closing conditions.

relyon is a subsidiary of TDK Electronics AG and is one of the leading technology providers in the field of atmospheric plasma technology. relyon develops modular systems and customized OEM components for industrial and medical applications and has an extensive international patent portfolio in the field of plasma technology. In recent years, Viromed has worked with relyon to develop the cold plasma medical devices in the ViroCAP® and PulmoPlas® product families. In addition, relyon is currently handling the production of these systems on behalf of Viromed.

Through this planned acquisition, Viromed will expand its value chain and gain direct access to relyon’s expertise.

Notifying person:

Uwe Perbandt, CEO Viromed Medical AG

Contact Viromed:

E-Mail: kontakt@viromed-medical.de